Lexicon (LXRX) Pharmaceuticals announced that it has closed screening and expects to complete enrollment ahead of schedule in PROGRESS studying LX9211, an orally-delivered, potent, selective, investigational small molecule inhibitor of adaptor-associated kinase 1, AAK1. The Company also updated its expectations for the timing of anticipated top-line data, from the second quarter of 2025 to the first quarter of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- Lexicon signs licensing agreement with Viatris for sotagliflozin
- Lexicon receives $25M upfront from Viatris for exclusive sotagliflozin license
- Lexicon to present Phase 3 trial design for sotagliflozin in HCM
- Lexicon announces departure of President, COO Jeff Wade
- Lexicon Pharmaceuticals Announces Executive Leadership Changes